Toni Mitchell Selected Research

sfericase

1/2019	Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
1/2018	Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toni Mitchell Research Topics

Disease

2	Human Influenza (Influenza) 01/2019 - 01/2018
1	Cachexia 07/2019
1	Inflammation (Inflammations) 07/2019
1	Neoplasms (Cancer) 07/2019
1	Pancreatic Neoplasms (Pancreatic Cancer) 07/2019
1	Infections 01/2019
1	Hyperplasia 02/2017
1	Dyspepsia (Indigestion) 02/2017

Drug/Important Bio-Agent (IBA)

2	sfericaseIBA 01/2019 - 01/2018
2	EndonucleasesIBA 01/2019 - 01/2018
1	CytokinesIBA 07/2019
1	Antiviral Agents (Antivirals)IBA 01/2019
1	ProdrugsIBA 01/2018
1	GastrinsIBA 02/2017
1	Esomeprazole (Nexium)FDA Link 02/2017
1	Proton Pump InhibitorsIBA 02/2017

Therapy/Procedure

1	Nutritional Support (Artificial Feeding) 07/2019
1	Therapeutics 02/2017